Revividal - A new biomedical solution for treatment of obesity
1 min read
Supporting satiety without drugs or surgery can improve weight management outcomes. Revividal is developing an ingestible gastric medical device to realize weight-loss designed to support satiety via mechanoreceptor activation, without systemic drugs or surgical intervention. During Health Holland Global Investor Forum 2026, Kristel De Ridder, CEO of Revividal, pitch their start-up and introduced their biomedical solution for treatment of obesity. Watch her pitch video to learn how it activates natural satiety mechanisms for weight-loss support.
More than 650 million people worldwide are obese and more than 1.9 billion people are overweight. Rising obesity rates, an overburdened healthcare system and lack of scalability of existing treatment options is leading to more and more weight-related health problems.
Revividal is a food-based, self-inflating and digestible gastric balloon, which you can take as a pill under the guidance of a professional.
With this medical device Revividal aims to make the treatment of obesity more widely accessible and cheaper.
Revividal is developing an ingestible gastric medical device to realize weight-loss designed to support satiety via mechanoreceptor activation, without systemic drugs or surgical intervention.
Are you also interested to pitch your company at the next edition of Health~Holland Global Investor Forum and Innovation for Health on 10-11 March 2027 in Utrecht, the Netherlands? Then sign up for the event newsletter to stay informed.
